Research and Development
Our research focuses on addressing ADME-Tox requirements and pioneering preclinical solutions.
DOWNLOAD CATALOGUE
ADME-Tox segment
Medtech Barcelona, through its main branch ReadyCell, manufactures ready-to-use cell-based models as a compelling alternative to animal testing, offering efficient solutions to improve candidate success in preclinical drug development.
In this context, we continuously expand our product portfolio to align with new therapeutic agents, the evolving demands of the pharmaceutical industry and research groups, and the valuable inputs from regulatory authorities.
Thanks to it, we are at the forefront of the ADME-Tox segment, providing cell-based models able to investigate the mechanisms involved in intestinal drug toxicity, drug-transporter interactions and active and passive drug absorption and secretion.
Future-oriented R&D Areas
We are interested in expanding our pipeline, which we actively pursue through several collaborations and projects:
Through active collaborations, we are developing ready-to-use cardiotoxicity assay with cardiomyocytes that will significantly enhance the accuracy and effectiveness of detecting cardiac adverse events in drug screening.
Our research aims to develop user-friendly human hepatocytes, essential tools for characterizing the metabolism and hepatotoxicity of xenobiotics. These liver models are vital tools for the pharmaceutical industry, facilitating comprehensive drug metabolism and safety assessment.
We are integrating CYP3A4 into our Caco-2 cell-based model. This advancement enhances the prediction of oral bioavailability by simultaneously evaluating drug absorption and CYP3A4-mediated metabolism, while also considering the role of P-gp efflux activity in influencing the pharmacokinetics of drug candidates.
We are continuously improving our patented shipping medium to better preserve the integrity of our cell models during transport allowing longer shipping times. By optimizing the formulation, we aim to provide even more reliable and reproducible assay conditions upon delivery.
Preclinical research
Permeability for non-small molecules
Our team is actively expanding the range of permeability and transport-drug interaction studies for substances other than small molecules: peptides, nutraceuticals and nanoparticles.
Do you have a passion for advancing drug discovery and biomedical research?
ReadyCell scientists are available to discuss tailored projects indicated for drug development and preclinical studies.
Public-private partnership projects
MedTech Barcelona is involved in several research projects with public and private organizations to push the boundaries of scientific innovation.
SEE PROJECT
SEE PROJECT
At ReadyCell, we are dedicated to sharing our knowledge and resources through different formats of interest. Explore our latest releases below.
Biotechnology company specialized in the development and commercialization of innovative solutions for the pharmaceutical industry and biomedical research.
